Promisia Integrative Limited – Third Quarter Sales Update
Promisia Integrative Limited (NZX:PIL) is a company focused on developing and marketing
unique therapeutic natural products with proven safety and efficacy from robust data. Our
goal is to add scientific methodology and validity to an industry that is often perceived as
unscientific.
DDI: +64 4 499 5563
E: info@promisia.com
W: promisia.com
Level 4, 22 Panama Street
PO Box 25396, Wellington
New Zealand 6146
19 October 2017
PROMISIA INTEGRATIVE LIMITED - THIRD QUARTER SALES UPDATE
The Directors of Promisia Integrative Limited (NZX: PIL) advise that sales for the third quarter ended 30
September 2017 were $516,336. Sales year to date for 2017 are $1,832,416, up 1.25% compared with the
same period in 2016.
The launch of Arthrem® in NSW, Australia, and the launch of Artevite® (the new dog joint supplement) in
the New Zealand market have commenced with the company’s marketing and distribution agents, in both
countries, establishing sales channels for these products. Television advertising of Arthrem® in NSW and
Artevite® in New Zealand will commence in early 2018.
An independent report shows that Arthrem retained its place as the number one joint supplement in New
Zealand pharmacies in dollar terms for the month of September 2017 and was the number two single
selling product in New Zealand pharmacies in dollar terms for the month of September 2017.
For further information please contact Mr Stephen Underwood, Chairman on 027 499 3387.
ENDS
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- BLT — BLIS Technologies Limited: Half Yearly Report to 30 September 20172017-11-19
“Page 4 o Fresh Breath Kit ® – BLIS K12 ® Lozenges plus a specially-formulated mouth wash and tongue scraper to treat halitosis and maintain fresh breath. o TravelProtect TM – BLIS K12 ® based regimen for immunity protection when travelling. o ElitePro TM - Developed…”
- AFT — AFT Pharmaceuticals Limited: Interim Report FY20182017-11-22
“Gross Margin Gross Profit grew 33% to $14 .3m (PCP $10.8m) driven by the operating revenue growth primarily in Australia and supported by growth in Rest of World and New Zealand. The Gross Profit Margin improved to 39% (PCP 36%), driven by the growth of the higher margin…”
- AFT — AFT Pharmaceuticals Limited: FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 20172017-11-22
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 Working Capital increased slightly to $23.9m (PCP $23.1m) with the $2.4m increase in inventory to $21.1m (PCP…”